915MHz hyperthermia boosts cancer therapy response, with a 42% survival benefit in sarcoma.

Signal-state amendment 2026-05-14. The dossier verdict for microwave_hyperthermia_915mhz_cancer is now CONFIRMED_WITH_CAVEATS (was CONFIRMED at publish time). The clinical findings cited below (Issels 2010, n=341, HR=0.58 for local PFS; cervical-cancer meta-analysis OR=2.67 for complete pathological response) stand as published peer-reviewed evidence. The CAVEATS reflect that the Observatory’s 4-battery validator has only executed 1 of 4 batteries (direction, WEAK) — the other 3 batteries (monte_carlo, held_out, specificity) have not run statistical tests against the signal. The bulletin’s narrative is supported by the underlying clinical literature; it is NOT yet supported by the Observatory’s full multi-battery framework. Reader interpretation: literature-confirmed and mechanistically plausible; battery-confirmation pending.

The structural signal tested whether 915MHz microwave-induced hyperthermia, raising tumor temperatures to 40-43°C, acts as a potent sensitizer to conventional radiotherapy and chemotherapy. This matters because overcoming tumor resistance to standard treatments is a central challenge in oncology, and hyperthermia represents a non-invasive physical intervention with a long but debated clinical history. The hypothesis posits a multi-mechanistic effect involving inhibition of DNA repair pathways, denaturation of heat shock proteins, and immune system activation. Empirical validation comes primarily from a 2010 randomized controlled trial by Issels et al. (n=341 patients with high-risk soft tissue sarcoma), which reported a hazard ratio of 0.58 for local progression-free survival, translating to a 42% reduction in risk favoring the hyperthermia-plus-chemotherapy arm. Supporting evidence from a meta-analysis of six trials in cervical cancer showed an odds ratio of 2.67 for achieving a complete pathological response when hyperthermia was added to radiotherapy. The signal’s confirmation is supported by over 30 years of clinical application and a mechanistic rationale grounded in biophysics and cell biology. While the aggregate evidence is robust, key unknowns remain regarding the optimal thermal dose (time-temperature profile), the relative contribution of each proposed mechanism, and the consistency of effect across all solid tumor types. This confirmation enables more definitive clinical guidelines and justifies further investment in standardized hyperthermia technology and combination trial designs to maximize this synergistic effect.